<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02680795</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-BEL-106</org_study_id>
    <nct_id>NCT02680795</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes</brief_title>
  <official_title>An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients With Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, nonrandomized study to determine the PK profiles of belinostat
      in patients with relapsed/refractory solid tumors or hematological malignancies who have
      heterozygous and homozygous UGT1A1*28 genotypes and wild-type UGT1A1 gene. Enrolled patients
      will be assigned to 1 of 3 cohorts (A, B, or C) based on their UGT1A1 genotype
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open-label, nonrandomized study to determine the PK profiles of belinostat
      in patients with relapsed/refractory solid tumors or hematological malignancies who have
      heterozygous and homozygous UGT1A1*28 genotypes and wild-type UGT1A1 gene. Enrolled patients
      will be assigned to 1 of 3 cohorts (A, B, or C) based on their UGT1A1 genotype

      Enrollment into all cohorts will occur simultaneously rather than sequentially. Belinostat
      will be administered via a 30-minute infusion once daily from Day 1 to Day 5 of one 21-day
      cycle. Clinical safety will be monitored in each patient. Blood samples for PK analysis will
      be collected from Day 1 to Day 3, and urine samples for PK analysis will be collected from
      Day 1 to Day 4.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma and urine concentrations of belinostat will be measured</measure>
    <time_frame>26 Weeks</time_frame>
    <description>PK will be measured for area under the time-concentration curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma and urine concentrations of belinostat will be measured</measure>
    <time_frame>26 Weeks</time_frame>
    <description>PK will be measured for steady state volume of distribution (Vdss)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma and urine concentrations of belinostat will be measured</measure>
    <time_frame>26 Weeks</time_frame>
    <description>PK will be measured for total body clearance (CLtot)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma and urine concentrations of belinostat will be measured</measure>
    <time_frame>26 Weeks</time_frame>
    <description>PK will be measured for fraction excreted unchanged (fe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma and urine concentrations of belinostat will be measured</measure>
    <time_frame>26 Weeks</time_frame>
    <description>PK will be measured for renal clearance (CLren)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma and urine concentrations of belinostat will be measured</measure>
    <time_frame>26 Weeks</time_frame>
    <description>PK will be measured for non-renal clearance (CLnonren)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma and urine concentrations of belinostat will be measured</measure>
    <time_frame>26 Weeks</time_frame>
    <description>PK will be measured for peak concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma and urine concentrations of belinostat will be measured</measure>
    <time_frame>26 Weeks</time_frame>
    <description>PK will be measured for half-life (t 1/2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess overall incidence of treatment emergent adverse events (TEAEs) using CTCAE version 4.03</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Assess Safety of belinostat in patients with wild type, heterozygous, and homozygousUGT1A1*28 genotypes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess any adverse events (AEs) (changes in physical exam or laboratory findings related to study medication dosing</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Assess Safety of belinostat in patients with wild type, heterozygous, and homozygousUGT1A1*28 genotypes</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>Wild Type UGT1A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A:
Wild Type UGT1A1, Belinostat IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous UGT1A1*28</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B:
Heterozygous UGT1A1, Belinostat IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Homozygous UGT1A1*28</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort C:
Homozygous UGT1A1, Belinostat IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belinostat IV</intervention_name>
    <description>Cohort A:
Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.</description>
    <arm_group_label>Wild Type UGT1A1</arm_group_label>
    <other_name>Beleodaq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belinostat IV</intervention_name>
    <description>Cohort B:
Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.</description>
    <arm_group_label>Heterozygous UGT1A1*28</arm_group_label>
    <other_name>Beleodaq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belinostat</intervention_name>
    <description>Cohort C:
Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.</description>
    <arm_group_label>Homozygous UGT1A1*28</arm_group_label>
    <other_name>Beleodaq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is diagnosed with advanced solid tumors or advanced hematological malignancy
             that is relapsed/refractory, for which no standard salvage therapy exists.

          2. Patient must have received at least 1 prior systemic therapy for the current
             malignancy and has recovered from any toxicity of the prior therapy at screening.

          3. Patient has adequate hematological and hepatic functions.

        Exclusion Criteria:

          1. Patient is taking UGT1A1 inhibitors (eg, atazanavir, gemfibrozil, indinavir,
             ketoconazole, sorafenib) at screening.

          2. Patient has HBV or HCV

          3. Patient has a known HIV positive diagnosis.

          4. Patient has congestive heart failure Class III/IV

          5. Patient has had previous exposure to belinostat.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nawazish Khan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Spectrum Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen McKenna</last_name>
    <phone>949-743-9332</phone>
    <email>karen.mckenna@sppirx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chander Vasandani</last_name>
    <phone>949-743-9284</phone>
    <email>chander.vasandani@sppirx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Bettino</last_name>
      <phone>562-693-4477</phone>
    </contact>
    <investigator>
      <last_name>Richy Agajanian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Smith</last_name>
      <phone>330-492-3345</phone>
    </contact>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2016</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>UGT1A1*28</keyword>
  <keyword>Belinostat</keyword>
  <keyword>beleodaq</keyword>
  <keyword>wild type genotypes</keyword>
  <keyword>heterozygous genotypes</keyword>
  <keyword>homozygous genotypes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Belinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

